Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Key Points

• JPMorgan Chase raised its price target on Terns from $44.00 to $44.50 and kept an overweight rating, though that target implies about a 15.5% downside from the stock's previous close.
• TERN is trading near $52.66—close to its 52‑week high of $53.19—with a $6.08 billion market cap, while analysts have a consensus "Hold" rating and a $55.14 consensus price target amid mixed recommendations.
• Insider selling has been notable (98,857 shares sold over the last 90 days, including CEO sales), insiders now own 1.5%, and the company recently beat quarterly EPS estimates at -$0.24 versus -$0.30.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) had its price objective hoisted by analysts at JPMorgan Chase & Co. from $44.00 to $44.50 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective would suggest a potential downside of 15.49% from the company's previous close.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Terns Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Barclays reissued an "equal weight" rating and set a $53.00 price target (down from $56.00) on shares of Terns Pharmaceuticals in a research report on Monday, March 30th. Citizens Jmp lowered Terns Pharmaceuticals from a "market outperform" rating to a "hold" rating in a research report on Thursday, March 26th. Mizuho set a $53.00 price target on Terns Pharmaceuticals in a research report on Friday, March 27th. Finally, William Blair lowered Terns Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $55.14.

Terns Pharmaceuticals Trading Up 0.1%

TERN traded up $0.05 during midday trading on Tuesday, hitting $52.66. The company's stock had a trading volume of 1,956,405 shares, compared to its average volume of 4,988,284. The firm has a market cap of $6.08 billion, a P/E ratio of -51.13 and a beta of -0.37. Terns Pharmaceuticals has a 52-week low of $2.21 and a 52-week high of $53.19. The firm has a 50-day moving average price of $45.09 and a two-hundred day moving average price of $32.87.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last released its quarterly earnings data on Thursday, April 2nd. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.06. On average, equities analysts expect that Terns Pharmaceuticals will post -1.19 EPS for the current year.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 942 shares of Terns Pharmaceuticals stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total transaction of $49,690.50. Following the sale, the insider directly owned 105,673 shares in the company, valued at $5,574,250.75. The trade was a 0.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer owned 288,976 shares in the company, valued at $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 98,857 shares of company stock worth $3,850,896 over the last 90 days. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Terns Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $25,000. GAMMA Investing LLC increased its holdings in Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company's stock worth $35,000 after purchasing an additional 770 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in Terns Pharmaceuticals during the 2nd quarter worth approximately $41,000. iA Global Asset Management Inc. purchased a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $43,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Terns Pharmaceuticals during the 2nd quarter worth approximately $46,000. 98.26% of the stock is currently owned by hedge funds and other institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.